Jun 09, 2025
Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting
May 07, 2025
Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson's Disease
Apr 30, 2025
Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer
Jan 08, 2025
Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson's Disease
Nov 12, 2024
Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at UBS Global Healthcare Conference
Oct 08, 2024
Aspen Neuroscience Announces Collaboration and License Agreement with Cell X Technologies
Sep 26, 2024
Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson's Disease
Jul 08, 2024
Aspen Neuroscience to Present at Stifel 2024 Cell Therapy Forum July 9
Jun 20, 2024
Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons
May 30, 2024
Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting
May 15, 2024
Aspen Neuroscience Receives CLIN2 Grant for ANPD001 from California Institute for Regenerative Medicine (CIRM)
May 15, 2024
Aspen Neuroscience Receives CLIN2 Grant for ANPD001 from California Institute for Regenerative Medicine (CIRM)
Apr 17, 2024
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson's Disease
Feb 14, 2024
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
Jan 16, 2024
Aspen Neuroscience Appoints Ana Sousa Chief Regulatory Officer
Aug 03, 2020
Aspen Neuroscience Announces Management Transition
Apr 01, 2020
Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease